Medical Care:网络管理有助提高糖尿病患者他汀类药物治疗依从性

2014-01-16 blue-clear http://www.medscape.

旧金山综合医院内科临床部和加利福尼亚大学的UrmimalaSarkar博士及其研究团队研究发现,糖尿病患者仅使用网络管理系统复诊,不仅提高了糖尿病患者他汀类药物治疗的依从性,而且降低LDL-C的水平。该研究结果发表在2013年12月26日的Medical Care杂志。Sarkar博士团队认为,利用网络预约门诊、查看化验结果、开具处方及与网站的服务人员进行交流,这种看病模式在医疗保健机构中会逐渐增

旧金山综合医院内科临床部和加利福尼亚大学的Urmimala Sarkar博士及其研究团队研究发现,糖尿病患者仅使用网络管理系统复诊,不仅提高了糖尿病患者他汀类药物治疗的依从性,而且降低LDL-C的水平。该研究结果发表在2013年12月26日的 Medical Care杂志。

Sarkar博士团队认为,利用网络预约门诊、查看化验结果、开具处方及与网站的服务人员进行交流,这种看病模式在医疗保健机构中会逐渐增多。

“利用个体化的干预模式来改善患者的依从性,不仅代价昂贵,而且多数情况下最终结果不理想”。KPNC高级研究员Andrew J.博士讲说,“相对于去药房配药,在线预约更为便捷,同时可降低药房运营成本。 伴随着药物治疗和临床结果的潜在收益,这应该是个双赢的模式。”

研究小组挑选了 17,760名服用他汀类药物的患者,并且这批患者曾使用过网络管理系统。受试者分为以下3组: 持续服用他汀类药物并通过通过网站复诊者3,287人,偶尔使用网站者5,418人,药房取药或者电话预约者9055人(对照组)。

基于患者取药的订单记录,进行他汀类药物依从性的计算,“依从不佳”定义为:患者在服药期间,超过20%的记录显示他们没去复诊。 对于基线时依从性不佳的3,887名患者,LDL-C水平作为次要评估标准。

随访周期为100天,(开始使用网站后第二次复诊),依从性不佳者,随访周期会适当延长。
首次随访发现,未使用网站的患者药物依从性不佳概率无明显的变化,偶然使用网站人群依从性不佳率从26%仅下降到24%, 持续通过网站复诊的患者依从性不佳率从22%下降至15%。

校正了混杂因素后(包括基线时药物依从性、年龄、性别、种族、服用的药物药物数量及门诊随访次数),持续使用网站患者依从性不佳率下降了6%,偶尔使用的人群未出现明显下降。

同时,依从性不佳且基线时LDL-胆固醇水平高于100mg/dl的患者,在使用网站复诊后,LDL-胆固醇水平下降了6%,而偶尔使用网站的人群LDL-C控制无明显差异。

Karter博士对结果表示惊讶,“如此简单的一个网上预约系统,可以使病人的血脂控制指标得到改善。”同时他也担心,“病人不应该被迫使用网上预约系统,该系统并非适合所有人群,我们在创新的同时,确保传统的方式不应被遗弃。”

原文出处:
Miriam E. Tucker.Statin Refill by Patient Portal Ups Adherence in Diabetes.Medscape January 09, 2014

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858582, encodeId=7fc518585826a, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Nov 02 23:40:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044344, encodeId=5c62204434435, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 14 05:40:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926768, encodeId=ac631926e68a5, content=<a href='/topic/show?id=2c7e8e78462' target=_blank style='color:#2F92EE;'>#药物治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87784, encryptionId=2c7e8e78462, topicName=药物治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Sep 19 13:40:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951684, encodeId=ae0b19516843a, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sun Aug 24 05:40:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319245, encodeId=c1bd131924583, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473760, encodeId=dbce14e376062, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533541, encodeId=16bf153354135, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606098, encodeId=a5601606098b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=)]
    2014-11-02 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858582, encodeId=7fc518585826a, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Nov 02 23:40:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044344, encodeId=5c62204434435, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 14 05:40:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926768, encodeId=ac631926e68a5, content=<a href='/topic/show?id=2c7e8e78462' target=_blank style='color:#2F92EE;'>#药物治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87784, encryptionId=2c7e8e78462, topicName=药物治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Sep 19 13:40:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951684, encodeId=ae0b19516843a, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sun Aug 24 05:40:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319245, encodeId=c1bd131924583, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473760, encodeId=dbce14e376062, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533541, encodeId=16bf153354135, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606098, encodeId=a5601606098b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858582, encodeId=7fc518585826a, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Nov 02 23:40:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044344, encodeId=5c62204434435, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 14 05:40:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926768, encodeId=ac631926e68a5, content=<a href='/topic/show?id=2c7e8e78462' target=_blank style='color:#2F92EE;'>#药物治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87784, encryptionId=2c7e8e78462, topicName=药物治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Sep 19 13:40:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951684, encodeId=ae0b19516843a, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sun Aug 24 05:40:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319245, encodeId=c1bd131924583, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473760, encodeId=dbce14e376062, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533541, encodeId=16bf153354135, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606098, encodeId=a5601606098b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1858582, encodeId=7fc518585826a, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Nov 02 23:40:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044344, encodeId=5c62204434435, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 14 05:40:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926768, encodeId=ac631926e68a5, content=<a href='/topic/show?id=2c7e8e78462' target=_blank style='color:#2F92EE;'>#药物治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87784, encryptionId=2c7e8e78462, topicName=药物治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Sep 19 13:40:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951684, encodeId=ae0b19516843a, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sun Aug 24 05:40:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319245, encodeId=c1bd131924583, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473760, encodeId=dbce14e376062, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533541, encodeId=16bf153354135, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606098, encodeId=a5601606098b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1858582, encodeId=7fc518585826a, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Nov 02 23:40:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044344, encodeId=5c62204434435, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 14 05:40:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926768, encodeId=ac631926e68a5, content=<a href='/topic/show?id=2c7e8e78462' target=_blank style='color:#2F92EE;'>#药物治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87784, encryptionId=2c7e8e78462, topicName=药物治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Sep 19 13:40:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951684, encodeId=ae0b19516843a, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sun Aug 24 05:40:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319245, encodeId=c1bd131924583, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473760, encodeId=dbce14e376062, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533541, encodeId=16bf153354135, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606098, encodeId=a5601606098b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=)]
    2014-01-18 fyxzlh
  6. [GetPortalCommentsPageByObjectIdResponse(id=1858582, encodeId=7fc518585826a, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Nov 02 23:40:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044344, encodeId=5c62204434435, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 14 05:40:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926768, encodeId=ac631926e68a5, content=<a href='/topic/show?id=2c7e8e78462' target=_blank style='color:#2F92EE;'>#药物治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87784, encryptionId=2c7e8e78462, topicName=药物治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Sep 19 13:40:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951684, encodeId=ae0b19516843a, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sun Aug 24 05:40:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319245, encodeId=c1bd131924583, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473760, encodeId=dbce14e376062, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533541, encodeId=16bf153354135, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606098, encodeId=a5601606098b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1858582, encodeId=7fc518585826a, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Nov 02 23:40:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044344, encodeId=5c62204434435, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 14 05:40:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926768, encodeId=ac631926e68a5, content=<a href='/topic/show?id=2c7e8e78462' target=_blank style='color:#2F92EE;'>#药物治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87784, encryptionId=2c7e8e78462, topicName=药物治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Sep 19 13:40:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951684, encodeId=ae0b19516843a, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sun Aug 24 05:40:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319245, encodeId=c1bd131924583, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473760, encodeId=dbce14e376062, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533541, encodeId=16bf153354135, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606098, encodeId=a5601606098b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=)]
    2014-01-18 海豹
  8. [GetPortalCommentsPageByObjectIdResponse(id=1858582, encodeId=7fc518585826a, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Nov 02 23:40:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044344, encodeId=5c62204434435, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 14 05:40:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926768, encodeId=ac631926e68a5, content=<a href='/topic/show?id=2c7e8e78462' target=_blank style='color:#2F92EE;'>#药物治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87784, encryptionId=2c7e8e78462, topicName=药物治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Sep 19 13:40:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951684, encodeId=ae0b19516843a, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sun Aug 24 05:40:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319245, encodeId=c1bd131924583, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473760, encodeId=dbce14e376062, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533541, encodeId=16bf153354135, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606098, encodeId=a5601606098b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 18 05:40:00 CST 2014, time=2014-01-18, status=1, ipAttribution=)]

相关资讯

JAMA:糖尿病患者使用电子病历与其看急诊、住院次数减少有关

据9月11日发表在《美国医学会杂志》上的一则研究披露,糖尿病患者使用综合医疗救治体系提供的一种门诊病人电子病历(EHR)与其看急诊及住院次数的适度减少有关,但与其去诊所就诊的次数变化无关。【原文下载】 经济与临床卫生信息技术健康(HITECH)法案授权在10年的时间里拨款高达270亿美元用以促进有意义的EHRs使用,并从2015年开始会对不使用EHR的做法加以处罚。在这些重大的激励措施下

BMJ:ACEI为糖尿病患者**降压药

我国台湾学者简国龙、杜裕康等新近发表的一项荟萃分析显示,血管紧张素转换酶抑制剂(ACEI)在成年糖尿病患者中是首选的抗高血压治疗药物。该研究发表于10月24日的《英国医学杂志》(BMJ)。   研究人员通过对PubMed、Medline、Scopus、Cochrane等数据的检索,分析了63项随机试验。这些试验在近37,000位患有糖尿病的成年人中评价了11种不同的降压治疗方案。研究终点

Hypertension:无糖尿病患者ACEI与小剂量噻嗪利尿剂联用对胰岛素作用影响不大

到目前为止关于降压治疗最大临床研究(Lipid-Lowering Treatment to Prevent Heart Attack Trial ,ALLHAT)发现利尿剂在降低某些心血管结局上优于其他降压药,但是与ACE抑制剂及钙离子拮抗剂相比,利尿剂增加新发2型糖尿病风险。来自北爱尔兰的研究人员McHenry CM等曾早些时候发现ACE抑制剂对胰岛素的作用是中性的。与单用ACE抑制相比,高剂量

糖尿病患者半数有耳聋、耳鸣

许多糖尿病患者年纪不大,却开始出现听力下降的情况,不仅听不清别人讲话,还时不时伴有耳鸣,严重者甚至耳聋,其实这都是糖尿病的不良反应,糖尿病可引起听力提早老化,流行病学显示,约半数患者有耳聋、耳鸣。 糖代谢异常 糖代谢异常可以造成内耳功能改变,因为糖和糖代谢提供了内耳主要的能量来源,血浆中持续高血糖可以导致淋巴中葡萄糖水平和内淋巴的直流电位改变,据此有学者认为由于葡萄糖代谢影响了内耳主动转运系统

Diabetes Care:老年患者血压和冠心病风险呈负相关

  美国一项研究表明,血压和冠心病风险之间存在U型相关或负相关,激进的血压控制(aggressive blood pressure control ,<120/70 mmHg)与冠心病风险升高具有相关性。论文5月20日在线发表于《糖尿病护理》(Diabetes Care)。   此项前瞻性队列研究共纳入17536例非洲裔美国人和12618例白人糖尿病患者。利用Cox比例

EAPCIP2013:CAD患者每日2次给药可缓解阿司匹林抵抗

巴黎——一项纳入92例患者的单中心交叉试验表明,在糖尿病合并冠状动脉疾病(CAD)患者中,阿司匹林每日2次给药方案阻断血小板聚集的效果明显优于总剂量相同的每日1次给药方案。 在欧洲经皮心血管介入学会(EAPCI)2013年会上,法国巴黎Lariboisière医院心脏科的Jean-Guillaume Dillinger医生报告称,与未患糖尿病的患者相比,糖尿病患者往往对心血管事